13F reference period
Q2 2026
Security Snapshot
Dermata Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DRMA) Institutional Ownership
CUSIP: 249845504
13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026
Institutions Reporting
13
Shares (Excl. Options)
122,513
Price
$1.29
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- DRMA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 122,513
- Total 13F value
- $158,042
- Portfolio coverage rank
- 0%
- Share change
- +16,021
- Value change
- +$20,668
- Number of holders
- 13
- Shares outstanding
- 4,270,578
- SEC-reported price per share
- $1.11
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- DRMA - Dermata Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 249845504.
- 13 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 7 to 13 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $128,853 to $158,042.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 13 institutions filings for Q2 2026.
Security key
249845504
13F reference period
Q2 2026
13F holders
13
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
DRMA full holder history
Dermata Therapeutics, Inc. SEC filings
Dermata Therapeutics, Inc. company facts
Dermata Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 249845504:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
DRMA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PROEHL GERALD T | 17% | -12% | $1,952,070 | +$312 | 694,687 | +0.02% | PROEHL GERALD T | 19 Feb 2026 |
| Van Hoose Kyri K. | 9% | $457,379 | 384,352 | Kyri K. Van Hoose | 27 May 2026 | |||
| ARMISTICE CAPITAL, LLC | 5% | $151,487 | 53,910 | Armistice Capital, LLC | 31 Dec 2025 |
As of 30 Jun 2026, 13 institutional investors reported holding 122,513 shares of Dermata Therapeutics, Inc. - Common Stock, $0.0001 par value per share (DRMA). This represents 2.9% of the company’s total 4,270,578 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5